PHILADELPHIA – October 22, 2015 ––ERT, the leading cloud platform solutions provider delivering clinical and scientific innovation through its patient-centric data collection and intelligence solutions, today announced that Accelovance, a Contract Research Organization (CRO) focusing in oncology, vaccines, and general medicine, has selected ERT’s Insights Cloud to replace the functionality of a traditional Clinical Trial Management System (CTMS).The Insights Cloud is an integrated solution that harmonizes data from any eClinical system and leverages real-time data analytics to automate and optimize trial management workflows.
“Data-driven decision making has been the objective of the clinical trial industry for some time, but the logistical hurdle of achieving that objective as a CRO is significant,” said Mary Mattes, Vice President of Data Management & Biostatistics at Accelovance. “CROs utilize many different clinical trial technologies across our customers and must be able to efficiently repeat our standard processes, regardless of the tools in use. The ERT Insights Cloud data-driven technology is exactly what a CRO needs to serve our customers efficiently – it positions us to deploy risk-based monitoring paradigms and provide sponsor visibility into the performance of their trials, all through one scalable cloud application.”
ERT’s Insights Cloud includes a technology-agnostic data hub with proprietary integration framework that enables rapid deployment and near real time data integration from leading data capture systems including IVR / IRT, EDC, and ePRO. This connectivity eliminates the need to manually enter or load data, and helps automate processes through an analytics engine that derives status information and computes performance metrics based on clinical and operational data from these systems. This provides users with comprehensive insight into the risk and performance of clinical trials with minimal system overhead. Insights Cloud’s data access and decision-ready analytics drive workflow solutions that enable sponsors and CROs to collaborate and ensure appropriate follow-up and intervention.
“ERT is extremely pleased to have found a highly collaborative customer in Accelovance. Their commitment to changing the clinical operations paradigm by using analytics to drive workflow and decisions is matched only by their commitment to complete transparency with their customers,” said Peg Regan, Vice President, eClinical Insights, at ERT. “We look forward to working together in innovating the next generation of CTMS to improve the efficiency of clinical trials.”
ERT recently conducted a webinar, “From CTMS to Clinical-Trials-Intelligence-Solution: How Technology Agnostic Integration & Analytics Automate Clinical Trials Management.” For complimentary access to the recorded webinar, click here.
ERT (https://www.ert.com) is a leading provider of high-quality patient safety and efficacy endpoint data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the widely deployed solutions in centralized Cardiac Safety, Respiratory, Suicide Risk Assessment, electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products.
ERT is a global organization with headquarters in Philadelphia, PA and offices throughout the U.S., and in Germany, Japan, Switzerland and the U.K.
Accelovance, Inc., headquartered in Rockville, MD, is an industry award-winning global Contract Research Organization (CRO) focused primarily in oncology, vaccines, and general medicine. As a clinical services provider to the pharmaceutical and biotechnology industries, Accelovance offers comprehensive clinical development services including management and implementation of Phase I-IV clinical trials and Clinical Engagement Solutions for recruitment, post-marketing surveillance, and long-term survival follow-up. For more information, visit the company’s Web site at www.accelovance.com.
Michael Keens, VP Business Development